The DOI matches its Crossref record.
Pharmacokinetics of losartan and its metabolite E‐3174 in relation to the CYP2C9 genotype
Abstract
Background And Aim: Losartan is metabolized by polymorphic CYP2C9 to E‐3174. Our aim was to evaluate the pharmacokinetics of losartan and E‐3174 in relation to the CYP2C9 genotype. Methods: A 50‐mg oral dose of losartan was given to 22 Swedish volunteers with different CYP2C9 genotypes. Losartan and E‐3174 were analyzed by HPLC in plasma and urine samples collected up to 24 hours after drug intake. Furthermore, losartan and E‐3174 were analyzed in 8‐hour urine samples collected from 17 Spanish subjects after a single oral dose of 25 mg losartan. Results: The maximum plasma concentration of E‐3174 was significantly (P < .05) lower in the CYP2C9*1/*3 (n = 5) and CYP2C9*2/*3 (n = 4) groups compared with the CYP2C9*1/*1 (n = 6) and CYP2C9*1/*2 (n = 3) groups and extremely low in 1 subject with the CYP2C9*3/*3 genotype. The ratio of the total losartan area under the plasma concentration–time curve (AUC) to the total E‐3174 AUC (AUC losartan/AUC E‐3174) was higher in the subject with the CYP2C9*3/*3 genotype (30‐fold) and also in the CYP2C9*1/*3 and *2/*3 groups (approximately 2‐ and 3‐fold, respectively) compared with the CYP2C9*1/*1 group. The plasma ratios correlated significantly with the 0‐ to 8‐hour urinary losartan/E‐3174 ratios. Among the total of 39 subjects, the urinary ratio was significantly higher in subjects with the CYP2C9*1/*3 (n = 10) and *2/*3 (n = 4) genotypes than in those with the CYP2C9*1/*1 genotype (n = 11; P < .01) and approximately 40‐fold higher in subjects with the CYP2C9*3/*3 genotype (n = 3). Conclusion: The CYP2C9*3 allele was shown to be associated with decreased formation of E‐3174 from losartan. The significant differences between genotypes in plasma and urine losartan/E‐3174 ratios and the good correlation between the plasma and urine ratios suggest that the losartan/E‐3174 ratio in 0‐ to 8‐hour urine specimens may serve as a phenotyping assay for CYP2C9 activity. Further studies in larger populations will be required to establish this. Clinical Pharmacology & Therapeutics (2002) 71, 89–98; doi: 10.1067/mcp.2002.121216
Overview
The claims and statistics of this paper haven’t been checked yet.
Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cited by
(2007) · PubMed · Cited by 953
Pharmacogenetics, Drug-Metabolizing Enzymes, and Clinical Practice
Gardiner, S. J., & Begg, E. J. (2006) · Pharmacological Reviews · doi:10.1124/pr.58.3.6 · Cited by 406
Repeated administration of berberine inhibits cytochromes P450 in humans
Guo, Y., Chen, Y., Tan, Z.-R., Klaassen, C. D., & Zhou, H.-H. (2012) · European Journal of Clinical Pharmacology · doi:10.1007/s00228-011-1108-2 · Cited by 137
Current Status of Research on Losartan in Tumour Therapy
Wang, H., Yuan, S., & Wang, H. (2026) · Journal of Cellular and Molecular Medicine · doi:10.1111/jcmm.70985 · Cited by 11
Metadata
- Authors
- Yasar, Ü., Forslund‐Bergengren, C., Tybring, G., Dorado, P., LLerena, A., Sjöqvist, F., Eliasson, E., & Dahl, M.
- Venue
- Clinical Pharmacology & Therapeutics
- Publisher
- Wiley
- Published
- 2002-01
- Volume
- 71
- Issue
- 1
- Pages
- 89-98
- ISSN
- 0009-9236 (ISSN-L)
- 1532-6535
- OpenAlex
- W2000747577
- Cited by
- 183
- References
- 0
- FWCI
- 10.61
- Type
- journal article
- Language
- en
- Open access
- closed
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
How to cite
Cite CoChat for the checks on this page, and the paper for its own findings.
- This page
- CoChat. (2026). Citation check: Pharmacokinetics of losartan and its metabolite E‐3174 in relation to the CYP2C9 genotype. https://app.cochat.ai/papers/10.1067/mcp.2002.121216
- The paper
- Yasar, Ü., Forslund‐Bergengren, C., Tybring, G., Dorado, P., LLerena, A., Sjöqvist, F., Eliasson, E., & Dahl, M. (2002). Pharmacokinetics of losartan and its metabolite E‐3174 in relation to the CYP2C9 genotype. Clinical Pharmacology & Therapeutics. https://doi.org/10.1067/mcp.2002.121216
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.
